Press coverage about Foamix Pharmaceuticals (NASDAQ:FOMX) has trended somewhat positive this week, according to Accern Sentiment. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. Foamix Pharmaceuticals earned a news impact score of 0.14 on Accern’s scale. Accern also assigned press coverage about the specialty pharmaceutical company an impact score of 45.4298608245084 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock’s share price in the near term.
Foamix Pharmaceuticals traded up $0.22, reaching $5.43, during mid-day trading on Wednesday, Marketbeat.com reports. 63,600 shares of the stock were exchanged, compared to its average volume of 122,202. The company has a market capitalization of $218.32 million, a PE ratio of -3.09 and a beta of 1.90. Foamix Pharmaceuticals has a 1 year low of $4.34 and a 1 year high of $7.45.
Get Foamix Pharmaceuticals alerts:Foamix Pharmaceuticals (NASDAQ:FOMX) last released its quarterly earnings results on Wednesday, May 9th. The specialty pharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.45) by ($0.24). The firm had revenue of $0.91 million for the quarter, compared to analysts’ expectations of $1.11 million. Foamix Pharmaceuticals had a negative return on equity of 103.64% and a negative net margin of 2,119.19%. equities research analysts predict that Foamix Pharmaceuticals will post -1.76 EPS for the current fiscal year.
A number of research analysts have recently commented on the company. HC Wainwright set a $12.00 price objective on Foamix Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, April 17th. ValuEngine upgraded Foamix Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Friday, May 11th. Finally, Zacks Investment Research downgraded Foamix Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Wednesday, May 2nd. One research analyst has rated the stock with a sell rating, one has issued a hold rating and three have assigned a buy rating to the company’s stock. The company has an average rating of “Hold” and an average price target of $9.67.
In related news, Director Stanley Hirsch sold 6,164 shares of the firm’s stock in a transaction that occurred on Sunday, May 13th. The stock was sold at an average price of $5.09, for a total transaction of $31,374.76. Following the transaction, the director now owns 12,672 shares in the company, valued at approximately $64,500.48. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Insiders have sold a total of 6,975 shares of company stock worth $35,522 in the last 90 days. 3.30% of the stock is currently owned by company insiders.
About Foamix Pharmaceuticals
Foamix Pharmaceuticals Ltd., a clinical-stage specialty pharmaceutical company, develops and commercializes foam-based formulations primarily for the treatment of moderate-to-severe acne, moderate-to-severe papulo-pustular rosacea, and other skin conditions in the United States and Germany. Its lead product candidates include FMX101, a novel topical foam formulation of the antibiotic minocycline, which has completed a double-blind and dose-ranging Phase II clinical trial for the treatment of moderate-to-severe acne; and FMX102 that has completed a Phase II clinical trial for the treatment of impetigo caused by staphylococcus aureus, including methicillin-resistant staphylococcus aureus.
No comments:
Post a Comment